Methotrexate-induced leukoencephalopathy is to be considered as a potential etiology in any patient presenting with stroke-like symptoms after receiving methotrexate. One of our cases suggests that the method of administration of the methotrexate can be IV or intrathecal and still results in leukoencephalopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628205PMC
http://dx.doi.org/10.1002/ccr3.1110DOI Listing

Publication Analysis

Top Keywords

methotrexate-induced leukoencephalopathy
8
leukoencephalopathy presenting
4
presenting stroke
4
stroke emergency
4
emergency department
4
department methotrexate-induced
4
leukoencephalopathy considered
4
considered potential
4
potential etiology
4
etiology patient
4

Similar Publications

Article Synopsis
  • Methotrexate is a key medication for treating childhood cancers like acute lymphoblastic leukemia but can lead to severe side effects such as neurotoxicity, specifically leukoencephalopathy, which usually presents with gradual neurological symptoms.
  • A case involving a 10-year-old boy showed acute neurological symptoms, including limb weakness and involuntary movements, after taking oral methotrexate, a rare occurrence compared to traditional administration routes like injection.
  • MRI scans revealed brain abnormalities consistent with methotrexate-induced neurotoxicity, highlighting the need for careful monitoring of neurological effects even with oral use of the drug.
View Article and Find Full Text PDF

Methotrexate (MTX) is used to treat acute lymphoblastic leukemia (ALL). It acts by inhibiting cell proliferation through its role as a folate antagonist. Despite its positive impact on patients' survival, high-dose MTX therapy carries risks, notably neurotoxic side effects such as subacute leukoencephalopathy that can mimic stroke symptoms.

View Article and Find Full Text PDF

Methotrexate-induced neurotoxicity is a well-defined side-effect of high-dose and intrathecal methotrexate with characteristic clinico-radiological findings and transient nature. Our experience in managing this entity in children with acute lymphoblastic leukemia(ALL) is reported here. All children with de novo ALLregistered from January 2016 through December 2021 who developed methotrexate-induced neurotoxicity were included.

View Article and Find Full Text PDF
Article Synopsis
  • New cancer treatments, especially immunotherapy, are helping patients live longer and feel less sick, but there are still problems that can come from these therapies.
  • Doctors who look at brain images, called neuroradiologists, can spot signs of these problems early on.
  • The article explains various complications from different treatments, like chemotherapy and radiation, and stresses how important it is for doctors to recognize these issues to help patients stay safe and healthy.
View Article and Find Full Text PDF

Methotrexate (MTX) is potent chemotherapeutic agent, often administered intrathecally to treat or prevent central nervous system involvement in lymphomas and leukemias, particularly T-cell lymphoblastic leukemia (T-LBL). MTX has been linked to adverse neurologic effects that mimic acute stroke, including facial drooping, hemiplegia, impaired consciousness, and seizures, as well as changes on imaging-known as MTX-induced leukoencephalopathy (LE). We report a case of a 17-year-old male diagnosed with T-LBL, who had been receiving MTX chemotherapy for 4 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!